Characteristics and Outcomes of IBD Patients with COVID-19 on Tofacitinib Therapy in the SECURE-IBD Registry

Inflamm Bowel Dis. 2021 Mar 15;27(4):585-589. doi: 10.1093/ibd/izaa303.

Authors

Manasi Agrawal¹, Erica J Brenner², Xian Zhang², Irene Modesto³, John Woolcott³, Ryan C Ungaro¹, Jean-Frederic Colombel¹, Michael D Kappelman²

Affiliations

¹ The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
² Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
³ Inflammation and Immunology, Global Medical Affairs, Pfizer Inc, New York, New York, USA.

No abstract available

Keywords: Crohn’s disease; coronavirus disease 2019; inflammatory bowel disease; outcomes; tofacitinib; ulcerative colitis.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Aged
COVID-19 / complications
COVID-19 / diagnosis*
COVID-19 / therapy
COVID-19 Testing
Child
Female
Humans
Inflammatory Bowel Diseases / complications
Inflammatory Bowel Diseases / drug therapy*
Male
Middle Aged
Piperidines / therapeutic use*
Prognosis
Protein Kinase Inhibitors / therapeutic use*
Pyrimidines / therapeutic use*
Registries
Severity of Illness Index
Young Adult

Substances

Piperidines
Protein Kinase Inhibitors
Pyrimidines
tofacitinib

Grants and funding